Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity

Lung adenocarcinoma accounts for ∼40% of lung cancers, the leading cause of cancer-related death worldwide, and current therapies provide only limited survival benefit. Approximately half of lung adenocarcinomas harbor mutations in TP53 (p53), making these mutants appealing targets for lung cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Turrell, Frances K., Kerr, Emma M., Gao, Meiling, Thorpe, Hannah, Doherty, Gary J., Cridge, Jake, Shorthouse, David, Speed, Alyson, Samarajiwa, Shamith, Hall, Benjamin A., Griffiths, Meryl, Martins, Carla P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580655/
https://www.ncbi.nlm.nih.gov/pubmed/28790158
http://dx.doi.org/10.1101/gad.298463.117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580655/
https://www.ncbi.nlm.nih.gov/pubmed/28790158
http://dx.doi.org/10.1101/gad.298463.117

Ejemplares similares